Fig. 8: CEBPA is required for the benefits of TRβ activation in vivo. | Nature Communications

Fig. 8: CEBPA is required for the benefits of TRβ activation in vivo.

From: TRβ activation confers AT2-to-AT1 cell differentiation and anti-fibrosis during lung repair via KLF2 and CEBPA

Fig. 8: CEBPA is required for the benefits of TRβ activation in vivo.

a Workflow of AAV-shCebpa delivery, BLM challenge, and GC-1 treatment. b Hydroxyproline level (n = 6, 6, 7, 6, 7, 6). c Total lung wet weight (n = 7, 6, 5, 6, 6, 6). d WBC counts (n = 6, 6, 6, 5, 6, 6) and protein content (n = 7, 7, 7, 6, 7, 6) in BALF. e Line plots of the percent survival from 7 to 21 days (n = 10, 20, 20). f Protein levels of fibrotic markers and AT1 cell markers. g Representative images of trichrome staining. Scale bar of whole sections, 3 mm; Scale bar of 10 × images, 100 μm. h–j Representative images of AT2 cell hyperplasia and quantification of AT1 cell differentiation in AT2-lineage cells after shCebpa delivery in the PNX model (n = 5). The value of n indicates biologically independent samples (b–e). Data of different sections from three biologically independent mice (i). Similar results were repeated in two biologically independent experiments. Scale bar, 50 μm. Throughout bars, mean ± SEM. P-values were obtained by one-way ANOVA with Turkey’s multiple comparison test and log-rank (e), respectively.

Back to article page